Adenocarcinoma of the prostate: Innovations in management

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 2, 1997, Pages 111-119

  Petrovich, Zbigniew ^a   Baert, Luc ^a,b   Bagshaw, Malcolm A ^c   Brady, Luther W ^d   Elgamal, Azis ^b   Goethuys, Hans ^b   Heilman, Hans P ^e   Kirkels, Wim J ^f   Lieskovsky, Gary ^a   Perez, Carlos A ^g   Van Poppel, Hein ^b   Williams, Richard D ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e DEPARTMENT OF CARDIOLOGY   (Germany)

^f ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF IOWA   (United States)

Author keywords

Diagnosis and management; Digital rectal examination; Prostate carcinoma; Prostate specific antigen; Transrectal ultrasound

Indexed keywords

ANTIANDROGEN; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LUTEINIZING HORMONE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89; TUMOR ANTIGEN;

ARTICLE; BONE PAIN; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; HYPERTHERMIC THERAPY; MALE; METASTASIS; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; QUALITY OF LIFE; TRANSRECTAL ULTRASONOGRAPHY;

ADENOCARCINOMA; BRACHYTHERAPY; DISEASE MANAGEMENT; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOTHERAPY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 0030935694     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199704000-00001     Document Type: Article

References (62)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA 1996;65:5-27.
2. Johansson JE. Watchful waiting for early stage prostate cancer. Urology 1994;43:138-42.
3. Catalona WJ. Surgical management of prostate cancer. Contemporary results with anatomic radical prostatectomy. Cancer 1995;75:1903-8.
4. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determination 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993;150:1856-9.
5. Perez CA, Hanks GE, Leibel SA, Zietman AL, Fuks Z, Lee RW. Localized carcinoma of the prostate (stages T1B, T1C, and T3). Review of management with external beam radiotherapy. Cancer 1993;72:3156-73.
6. Babaian RJ, Kojima M, Saitoh M, Ayala AG. Detection of residual prostate cancer after external radiotherapy. Cancer 1995;75:2153-8.
7. Petrovich Z, Lieskovsky G, Freeman J, et al. Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate. Cancer 1995;76:1621-8.
8. Mettlin C, Murphy GP, Menck H. Trends in the treatment of localized prostate cancer by radical prostatectomy: observations from the Commission on Cancer National Database, 1985-1990. Urology 1994;43:488-92.
9. Franks LM. Etiology, epidemiology and pathology of prostatic cancer. Cancer 1973;32:1092-5.
10. Sakr WA, Haas GP, Cassin BF, Powks JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-89.
11. Bostwick DG. Prostatic intraepithelial neoplasia (PIN). Urology 1989;34(suppl):16-22.
12. Adolfsson J. Deferred treatment of low grade T3 prostate cancer without distant metastases. J Urol 1993;149:326-9.
13. Chodak GW, Thistea RA, Gerber GJ, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
14. Epstein JL, Walsh PC, Marue C, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1C) prostate cancer. JAMA 1994;271:368-74.
15. Douglas TH, Sesterhen IA, Moul JDN, McLeod DG. The significance of PSA detected, nonpalpable adenocarcinoma of the prostate (stage T1C). J Urol 1995;153(suppl):251A.
16. Adami HO, Baron JA, Rothman KJ. Ethics of prostate cancer screening trial. N Engl J Med 1994;343:958-60.
17. Catalona WJ. Screening for prostate cancer: enthusiasm. Urology 1993;42:113-5.
18. Chodak GW. Questioning the value of screening for prostate cancer in asymptomatic men. Urology 1993;42:116-8.
19. Schroeder FH. Detection of prostate cancer. Screening the whole population has not yet been shown to be worthwhile. Br Med J 1995;310:140-1.
20. Schroeder FH, Denis LJ, Kirkels W, De Konig HJ, Standaert B. European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies. Cancer 1995;76:129-34.
21. Babaian RJ, Sayer J, Podoloffg DA, Stelhammer LC, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with In-111-labeled monoclonal antibodies CYT-356. J Urol 1994;152: 1952-5.
22. Kahn D, Miller S, Gerstbrein J, Macquire R, Williams RD. Accuracy of In-111 capromab pendetide Mab scan for detecting prostate fossa tumor recurrence following radical prostatectomy. J Urol 1995;153:519A.
23. Meredith RH, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate cancer with radiolabeled antibody CC49. J Nucl Med 1994;35:1017-22.
24. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358-68.
25. Stamey TA. Second Stanford Conference on International Standardization of Prostate Specific Antigen Immunoassays. Urology 1995;45:173-84.
26. Stenman UH, Hakama M, Knek P, et al. Serum concentration of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.
27. Elgamal AA, Billen J, Van de Voorde WM, et al. Extraprostatic sources of PSA, does it infer the subjective biochemical recurrence after radical prostatectomy? J Urol 1995;153:518A.
28. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 1983;4:473-85.
29. Licht MR, Klein EA, Tuason L, Levin H. Impact of bladder neck preservation during radical prostatectomy on continence and cancer control. Urology 1994;44:883-7.
30. Weldon VE, Tavel FR, Neuwirth H, Cohen R. Patterns of positive specimen margins and detectable PSA after radical perineal prostatectomy. J Urol 1995;153:1565-9.
31. Turner R, Belt E. A study of 229 consecutive cases of total perineal prostatectomy for cancer of the prostate. J Urol 1957;77: 62-77.
32. Van Poppel H, Baert L. Clinical results of radical prostatectomy. Contrib Oncol 1994;47:57-72.
33. Lieskovsky G. Technique of radical retropubic prostatectomy (Campbell's procedure) with limited pelvic lymph node dissection. In: Skinner DG, Lieskovsky G, eds. Diagnosis and management of genitourinary cancer. Philadelphia: W.B. Saunders 1988:735-52.
34. Gibbons RP, Cole BS, Richardson RG, et al. Adjuvant radiotherapy following radical prostatectomy: results and complications. J Urol 1986;135:65-8.
35. Schulman CC, Sassine AM. Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol 1993;24:450-5.
36. Van Poppel H, De Ridder D, Elgamal AA, et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer. Interim results of a prospective randomized trial. J Urol 1996.
37. Bagshaw MA, Cox RS, Ramback JE. Radiation therapy for localized prostate cancer: justification for long term follow-up. Urol Clin North Am 1990;17:787-802.
38. Perez CA, Lee HK, Georgiou A, Logsdon MD, Lai PP, Lockett MA. Technical and tumor related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993;26:581-91.
39. Pilepich MV, Sause WT, Shipley W, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23.
40. Bagshaw MA. The challenge of radiation treatment of carcinoma of the prostate. In: Lepor H, Lawson RK, eds. Prostate diseases. Philadelphia: W.B. Saunders, 1993:326-46.
41. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: long term results. J Urol 1994;152:1781-5.
42. Hilaris BS, Whitmore WF, Batata MA, Barzel W, Tokita N. I-125 implantation of the prostate: dose response considerations. Front Radiat Ther Oncol 1978;12:82-90.
43. Batata MA, Hilaris BS, Chu FCH, et al. External beam versus brachytherapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1984;10(suppl 2):116.
44. Brady LW, Koprowski C, Borofsky AM, Lightfoot DA. Cancer of the prostate: brachytherapy techniques. In: Sauer R, ed. Interventional radiation therapy: techniques. Berlin: Springer, 1991:245-55.
45. Whitmore WF. Clinical management of prostate cancer. In: Raymond JP, Ojasso T, eds. Proceedings of a satellite symposium of the 3rd International Congress on Hormones and Cancer. New York: Raven Press, 1988:88-97.
46. Blasko JC, Grimm PD, Ragde H. External beam irradiation with palladium-103 implantation for prostate carcinoma. Int J Radiat Oncol Biol Phys 1994;30(suppl 1):219.
47. Perez CA, Lee HK, Georgiou A, Lockett MA. Technical factors affecting morbidity in definitive irradiation for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994;28: 811-9.
48. Bagshaw MA, Cox RS, Ramback JE. Radiation therapy for localized carcinoma of the prostate: justification for long-term follow-up. Urol Clin North Am 1990;17:787-802.
49. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1993:71(suppl): 1098-109.
50. Huggins C, Hodges WW. Studies on prostatic cancer: effects of castration, of estrogen and androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
51. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the VACURG studies. NCI Monogr 1988;7:165-70.
52. Chodak GH. LHRH agonists for treatment of advanced prostate carcinoma. Urology 1989;33(suppl 5):42-4.
53. Labrie F, Dupont A, Balanger A, et al. New hormonal therapy in prostatic carcinoma: combined treatment with LHRH agonist with an antiandrogen. Clin Invest Med 1982;5:267-75.
54. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
55. Denis U, Whelan P, De Mauro JL, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993;42:119-30.
56. Laing HH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-22.
57. Porter AT, McEwan AJ, Powe GE, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
58. Overgaard J, Gonzalez-Gonzalez D, Hulshof MCCM, et al. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 1995;345:540-3.
59. Petrovich Z, Emami B, Kapp D, et al. Regional hyperthermia in patients with recurrent genitourinary cancer. Am J Clin Oncol 1991;14:472-7.
60. Petrovich Z, Ameye F, Baert L, et al. New trends in the treatment of benign prostatic hyperplasia and carcinoma of the prostate. Am J Clin Oncol 1993;16:187-200.
61. Debicki P, Astrahan MA, Ameye F, et al. Temperature steering in the prostate by simultaneous transurethral and transrectal hyperthermia. Urology 1992;40:300-7.
62. Debicki P, Okoniewski M, Okoniewska E, et al. Cooled microwave transrectal applicator for adjustable directional beam tor prostate treatment. Int J Hyperth 1995;11:95-108.